| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Z-LLNle-CHO | GDSC1000 | pan-cancer | AAC | -0.046 | 0.3 |
| mRNA | quizartinib | CTRPv2 | pan-cancer | AAC | -0.039 | 0.3 |
| mRNA | QL-XII-47 | GDSC1000 | pan-cancer | AAC | 0.031 | 0.3 |
| mRNA | GSK4112 | CTRPv2 | pan-cancer | AAC | 0.038 | 0.3 |
| mRNA | CI-976 | CTRPv2 | pan-cancer | AAC | -0.04 | 0.3 |
| mRNA | FMK | GDSC1000 | pan-cancer | AAC | -0.035 | 0.4 |
| mRNA | ISOX:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.035 | 0.4 |
| mRNA | alisertib | CTRPv2 | pan-cancer | AAC | 0.033 | 0.4 |
| mRNA | nelarabine | CTRPv2 | pan-cancer | AAC | -0.04 | 0.4 |
| mRNA | ciclopirox | CTRPv2 | pan-cancer | AAC | -0.033 | 0.4 |